Classes
DEA Class; Rx
Common Brand Names; Aczone
- Antileprosy Agents,
- Acne Agents, Topical
Description
Synthetic sulfone chemically similar to sulfonamides
Has antiinfective and immunosuppressive properties
Agent of choice for all forms of leprosy; used for PCP prophylaxis; used in combination with pyrimethamine for prevention of toxoplasmosis in AIDS patients; used for various dermatologic disorders and topically for acne.
Indications
Indicated for the treatment of dermatitis herpetiformis.
Contraindications
Hypersensitivity to drug or component
Adverse Effects
- Hemolysis
- Methemoglobinemia
- Reactional states (ie, abrupt changes in clinical activity occurring during any leprosy treatment; classified as reversal of erythema nodosum leprosum reactions)
- Insomnia
- Headache
- Exfoliative dermatitis
- Photosensitivity
- Nausea
- Vomiting
- Anemia
- Leukopenia
- Agranulocytosis
- Hepatitis
- Cholestatic jaundice
- Peripheral neuropathy (usually in nonleprosy patients)
- Blurred vision
- Tinnitus
- SLE
Warnings
May cause blood dyscrasias (eg, agranulocytosis); monitor closely
Peripheral neuropathy may occur
Toxic epidermal necrolysis and other dermatologic reactions may occur
Use caution when treating patients with hypersensitivity to sulfonamides
Bacterial and fungal superinfections may occur from prolonged treatments
Pregnancy and Lactation
Pregnancy category: C
Lactation: Enters breast milk; not recommended (AAP Committee states “compatible with nursing
Maximum Dosage
Leprosy, up to 100 mg/day PO; dermatitis herpetiformis, up to 300 mg/day PO; relapsing polychondritis, up to 200 mg/day PO; for acne topical use, 5% gel 2 applications/day topically or 7.5% gel 1 application/day topically.
Leprosy, up to 100 mg/day PO; dermatitis herpetiformis, up to 300 mg/day PO; relapsing polychondritis, up to 200 mg/day PO; for acne topical use, 5% gel 2 applications/day topically or 7.5% gel 1 application/day topically.
Leprosy, up to 100 mg/day PO; dermatitis herpetiformis, up to 300 mg/day PO; relapsing polychondritis, up to 200 mg/day PO; for acne topical use, 5% gel 2 applications/day topically or 7.5% gel 1 application/day topically.
12 years: Maximum oral dosage information not established; for acne topical use, 5% gel 2 applications/day topically or 7.5% gel 1 application/day topically.
9 to 11 years: Maximum oral dosage information not established; for acne topical use, 7.5% gel 1 application/day topically, safety and efficacy of 5% gel not established.
1 to 8 years: Maximum oral dosage information not established; safety and efficacy of topical gel not established.
Maximum oral dosage information not established; safety and efficacy of topical gel not established.
Safety and efficacy not established.
How supplied
Dapsone
tablet
- 25mg
- 100mg
topical gel
- 5% (30g, 60g, 90g)
- 7.5% (30g, 60g, 90g)
